- Home
- RMAX vs NKTX Comparison
RMAX vs NKTX Comparison
Compare RMAX & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- NKTX
- Stock Information
- Founded
- RMAX 1973
- NKTX 2015
- Country
- RMAX United States
- NKTX United States
- Employees
- RMAX N/A
- NKTX N/A
- Industry
- RMAX Real Estate
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- RMAX Finance
- NKTX Health Care
- Exchange
- RMAX Nasdaq
- NKTX Nasdaq
- Market Cap
- RMAX 161.9M
- NKTX 131.3M
- IPO Year
- RMAX 2013
- NKTX 2020
- Fundamental
- Price
- RMAX $7.68
- NKTX $1.93
- Analyst Decision
- RMAX Hold
- NKTX Strong Buy
- Analyst Count
- RMAX 2
- NKTX 6
- Target Price
- RMAX $9.75
- NKTX $15.00
- AVG Volume (30 Days)
- RMAX 126.0K
- NKTX 657.1K
- Earning Date
- RMAX 05-01-2025
- NKTX 05-20-2025
- Dividend Yield
- RMAX N/A
- NKTX N/A
- EPS Growth
- RMAX N/A
- NKTX N/A
- EPS
- RMAX 0.44
- NKTX N/A
- Revenue
- RMAX $303,865,000.00
- NKTX N/A
- Revenue This Year
- RMAX N/A
- NKTX N/A
- Revenue Next Year
- RMAX $1.25
- NKTX N/A
- P/E Ratio
- RMAX $17.54
- NKTX N/A
- Revenue Growth
- RMAX N/A
- NKTX N/A
- 52 Week Low
- RMAX $6.90
- NKTX $1.31
- 52 Week High
- RMAX $14.31
- NKTX $8.23
- Technical
- Relative Strength Index (RSI)
- RMAX 46.14
- NKTX 51.05
- Support Level
- RMAX $7.39
- NKTX $1.81
- Resistance Level
- RMAX $8.22
- NKTX $2.16
- Average True Range (ATR)
- RMAX 0.34
- NKTX 0.16
- MACD
- RMAX 0.09
- NKTX -0.02
- Stochastic Oscillator
- RMAX 45.49
- NKTX 25.53
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.